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Background: Urinary tract infections (UTIs) are among the most commonly occurring bacterial infections,
particularly in pregnant women. Canephron® N (Bionorica, Germany) is a phytotherapeutic medicinal product that
has pleiotrophic effects on the urinary system, including diuretic, spasmolytic, anti-inflammatory, antimicrobial
and nephroprotective effects. The purpose of this retrospective study was to assess the safety of Canephron® N
when used in the first trimester of pregnancy for the treatment of UTIs.
Methods: This was a retrospective, multi-center study that evaluated the effects of Canephron® N in 384 women
who had used the herbal drug during the first trimester of pregnancy (between 2004 and 2009), and whose
pregnancies ended in live births. The endpoints assessed in this study were the presence of congenital defects in
the newborn.
Results: There were no significant differences in the incidence of congenital malformations in newborns whose
mothers had taken Canephron® N in the first trimester of pregnancy, compared to the national statistical data for
the Kiev population during the same period. The majority of newborns (>65 %) whose mothers had received
Canephron® N during the first trimester of pregnancy had Apgar scores of 8 or above, indicating an excellent
safety status.
Conclusions: The results from our study indicate that the use of Canephron® N during the first trimester of
pregnancy was not associated with any teratogenic, embryotoxic or fetotoxic effects on the fetus.
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Background
Urinary tract infections (UTIs) are among the most
commonly occurring bacterial infections, particularly in
pregnant women. Pregnancy is associated with specific
physiological, structural and functional alterations in the
urinary tract which facilitate bacterial growth and as-
cending infections [1]. Between 5 and 10 % of women
experience a UTI during pregnancy, usually asymptom-
atic bacteriuria, acute cystitis and pyelonephritis [2]. The
majority of UTIs are caused by bacterial species of en-
teric origin, namely Escherichia coli, which accounts for
70–85 % of cases [3], as well as Klebsiella pneumoniae,
Staphylococcus aureus and the Group B streptococci
[4–6]. If not properly treated, these infections can have
serious consequences for the mother and fetus increas-
ing the risk of pre-eclampsia, premature birth and low
neonatal birth weight [1].
Antibiotics are frequently prescribed for the treatment
of UTIs in pregnant women. Because of altered drug
pharmacokinetics during pregnancy and the possibility
of drug transfer across the placental barrier, the use of
antibiotics during pregnancy should be approached with
caution [7, 8]. Due to their potential teratogenic effects,
certain antibiotics are unsuitable for use in pregnant
women [9]. Antimicrobial agents considered safe in preg-
nancy are of the β lactam class including the penicillins,
cephalosporins and fosfomycin trometamol [6, 10].
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Nevertheless, the use of antibiotics in general is associated
with adverse events, including allergic reactions, gastro-
intestinal side-effects, and cardiac arrhythmia [11, 12], and
these should be administered with utmost caution during
pregnancy. In addition, the number of antimicrobial
agents safe for use during pregnancy is further limited by
the emergence of drug resistance amongst various bacter-
ial species [6, 13]. Thus, there is a need for alternative
treatment modalities for addressing UTIs that occur dur-
ing pregnancy.
Canephron® N (Bionorica, Germany) is a phytothera-
peutic medicinal product that consists of a fixed com-
bination of centaury herb (Centaurium sp.), lovage
root (Levisticum officinale Koch) and rosemary leaves
(Rosmarinus officinalis L.). The plant components
present in the drug has been shown to have pleio-
trophic effects on the urinary system, including diur-
etic [14, 15], spasmolytic [16, 17], anti-inflammatory
[18–20], antimicrobial [21–24] and nephroprotective
effects [25]. Clinical data has revealed a therapeutic
benefit in patients with UTIs, nephrolithiasis or uro-
lithiasis [26, 27]. Canephron® N has been available on
the European market for over 40 years and is regis-
tered as a traditional herbal medicine but is currently
not licensed for use during pregnancy and lactation.
Outside of the European Union (EU), however, it is
one of the most frequently-prescribed phytotherapeutic
medicines in pregnant women for the treatment of
upper and lower UTIs. Although clinical studies in
pregnant women have demonstrated Canephron® N to
be safe and well tolerated, thus far no studies have fo-
cused specifically on its safety aspects when used dur-
ing the first trimester of pregnancy.
The purpose of this retrospective study was to assess
the safety of Canephron® N when used in the first tri-
mester of pregnancy for the treatment of UTIs. The
main endpoint of this study was the presence of con-
genital defects in the newborn.
Methods
Study design
This was a retrospective, multi-center study that evalu-
ated the effects of Canephron® N in 384 women who
had used the herbal drug during the first trimester of
pregnancy, and whose pregnancies ended in live births.
All the women were monitored up to the end of preg-
nancy at the Isida Obstetrics and Gynecology Clinic,
Institute of Pediatrics, Obstetrics and Gynecology of
the Ukrainian Academy of Medical Sciences, from
2004 to 2009. All patients provided written informed
consent regarding the use of their data for study pur-
poses. The data in national registry is only provided as
frequency (in % of malformation) in working papers.
Therefore exact number of control patients cannot be
provided. Nonethless, the data is verified and reported
in national registry.
Study population and Canephron® N treatment
Since an individual’s parity status is known to have a
substantial impact on the outcome of a pregnancy [28],
and the number of multiparous cases was not sufficient
for a separate study, we included the primiparous
(singleton) and multiparous cases in our evaluation. All
participants had to have taken Canephron® N for at
least 14 days during the first trimester of pregnancy, for
the treatment of UTIs. The Canephron® N daily dosage
used was 6 tablets or 150 drops. In the majority of
cases, the women took Canephron® N before becoming
aware of their pregnancies. The main exclusion criteria
were the presence of hereditary diseases, multiple preg-
nancies, and chronic exposure to known toxic or geno-
toxic substances.
Endpoints
The main endpoint of this study was the presence of
congenital defects in the newborn. Furthermore, intra-
uterine developmental defects were assessed according
to the World Health Organization (WHO) International
Classification of Diseases (ICD)-10 classification [29].
Specifically, the presence of congenital malformations
of the genital organs, congenital malformations of the
urinary system, congenital malformations and deform-
ities of the musculoskeletal system and other congenital
malformations were evaluated [29]. The results ob-
tained were compared against the national statistical
data for Kiev during the same 5-year period from
primiparous pregnancies in women who had not used
Canephron® N. The status of the newborn infant was
evaluated using the 10-point Apgar scoring system one
minute after birth [30].
In case there was a pathological pregnancy and/or
developmental disorder in the newborn, further evalua-
tions were performed in order to assess the relation-
ship between the malformations and Canephron N®
intake (including the duration of drug administration,
administration of other medications, the mother’s age,
presence of defects in the family, laboratory data, ex-
posure to other known risk factors such as smoking or
some professional hazards). The presence of congenital
malformations in the infant was evaluated alongside
the timing of when the mother took Canephron® N
(using the first day of the last menstrual period as a
point of reference).
Statistical analysis
Statistical analysis of the results was performed using
Statistics for Windows® (version 5.3, Statsoft, USA).
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The relative risk (RR) ratios were calculated according
to the following formulas:
RR ¼ p1=p2
Where RR = relative risk, p1 = frequency of the event
in the experimental group, and p2 = frequency of the
event in the control group.














where SE = standarderror 0.05,
r1 and r2 = number of events in the experimental and
control groups,
n1 and n2 = number of patients in the experimental and
control groups,
95 % CI confidence interval = loge RR ± 1.96 × SM.
Results
The age of the participants ranged from 17 to 39 years
(average 21 ± 2.2 years). A total of 170 (44.3 %) of the
women were primiparous and 214 (55.7 %) were multip-
arous. Of the 384 women, 361 took Canephron® N tab-
lets (6 tablets daily), and 23 received Canephron® N
drops (150 drops daily). The average duration of the
treatment was 23 ± 1.25 days. In 196 cases (51.05 %),
Canephron® N was used as a monotherapy and in 188
cases (48.95 %) it was used as part of combination ther-
apy (alongside the antibacterial agents phosphomycin,
aminopenicillins, and cephalosporins). The indications
for treatment with Canephron® N in the study popula-
tion are summarized in Table 1.
There were no significant differences in the incidence
of malformations in newborns whose mothers had taken
Canephron® N in the first trimester of pregnancy, com-
pared to the national statistical data for the Kiev popula-
tion during the same period 2004–2010 (Table 2). Out
of the 384 women who took Canephron® N during the
first trimester of pregnancy, a total of 14 (3.65 %) gave
birth to infants with congenital malformations. This per-
centage is similar to that for the general Kiev population
during this period (3.71 % In according to report of State
Institution “Center for Health Statistics of the Ministry
of Health of Ukraine”.
There were two cases of malformations of the urinary
system in the Canephron® N population (both renal
agenesis). There was one case of duplication of the pel-
vicalyceal system and one case of ectopic pelvic kidney.
Cardiac malformations included transposition of the
great arteries, atrial septal defect and Ebstein’s anomaly.
Nervous system malformations included agenesis of the
corpus callosum, brain cyst, and congenital hydroceph-
alus with ventriculomegaly. Digestive system malforma-
tions consisted of anal atresia and pylorostenosis.
Malformations of the musculoskeletal system com-
prised absence of the distal phalanx of the finger and
syndactyly of the foot.
Next, we examined the relationship between the tim-
ing of Canephron® N administration in the first trimester
of pregnancy and the presence of any congenital malfor-
mations in the newborn (Table 3). The timing of
Canephron® N intake was assessed relative to the first
day of the last menstrual period.
Out of the 4 women who took Canephron® N at the
earliest and most vulnerable period of pregnancy (Day
29–50), none of their infants had congenital malforma-
tions. Of the 106 women who took Canephron® N be-
tween Day 51–70, 4 gave birth to infants with congenital
malformations, and 10 of the 274 women who took
Canephron® N between Day 71–84 gave birth to infants
with congenital malformations. The incidence of these
malformations is similar to that of the general Kiev
population.
Table 1 Indications for treatment with Canephron® N in the
study population
Indication n (%)
Chronic lower urinary tract infection (non-acute) 79 (20.6)
Acute cystitis or exacerbation of chronic cystitis 21 (5.5)
Prophylaxis for chronic pyelonephritis (non-acute) 203 (52.9)




Chronic glomerulonephritis 29 (7.5)
Table 2 Incidence of developmental defects in newborns of
the study population, compared to national statistical data of
the general Kiev population during the same period
Total developmental
defects in the study
population (N = 384)
Total developmental
defects in the general
Kiev population 3.71 %






Urinary tract 4 28.6 34.7













Total 14 (3,65 %
from 384)
100 100
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We calculated the RR and the 95 % confidence interval
(CI) of developing congenital birth defects in newborns
whose mothers were taking Canephron® N in the first
trimester of pregnancy. The RR was 0.941 (95 % CI:
0.526–1.68), indicating the absence of any effects of
Canephron® N on the incidence of congenital birth de-
fects in our study. Finally, the status of the newborns
was evaluated one minute after birth using the Apgar
scoring system (Fig. 1). Using the Apgar scoring system,
each of five main characteristics (heart rate, respiratory
effort, muscle tone, reflex irritability, and color) is
assigned a value of 0 to 2. The total score is the sum of
the five sub-scores, with a score of 7 or more indicating
that the new-born baby’s condition is good to excellent
[30]. The majority of newborns had scores of 8–10
points on the Apgar scale, indicating that their condition
was excellent, and suggesting that the use of Canephron®
N during the first trimester of pregnancy did not affect
the general status of the newborns.
Discussion
Inflammatory diseases of the urinary system are among
the most commonly-occurring diseases in pregnant
women [31]. Due to hormone-related dilation of the
renal pelvis and ureters, pregnant women have increased
risk of bacterial invasion of the kidneys and pyeloneph-
ritis [31]. During pregnancy, bacteriuria that progresses
to pyelonephritis has been associated with poor out-
comes for the mother and child. UTIs during pregnancy
increase the risk of maternal hypertension, anemia, and
pre-term labor, as well as low-birth weight [32, 33].
Therefore, addressing UTIs that occur during preg-
nancy is an important means for preventing pregnancy
complications.
In the Ukraine, Canephron® N is a frequently-used
phytotherapeutic medicine for the treatment of UTIs in
pregnant women. The drug has been shown to have
pleiotrophic effects on the urinary system, including di-
uretic, spasmolytic, anti-inflammatory, antimicrobial and
nephroprotective effects [14]. Our study was conducted
in order to establish the safety and teratogenic potential
of Canephron® N when used during this critical period.
The first trimester of pregnancy marks a period of cru-
cial morphogenetic events, when the fetus is particularly
susceptible to morphologic alterations due to adverse
environmental exposures [34]. Since no data is currently
available on the safety of Canephron® N during this
Table 3 Timing of Canephron® N administration in the first
trimester of pregnancy and the presence of congenital
malformations in the newborn
Timing (number of days




N = 14 (100 %) N = 370 (100 %)
29–50 (n = 4) - 4 (1.08)
51–70 (n = 106) 4 (28.6) 102 (27.6)
71–84 (n = 274) 10 (71.4) 264 (71.3)
Total 14 (100) 370 (100)
Fig. 1 Apgar scores of newborns whose mothers used Canephron® N during the first trimester of pregnancy. Red: Newborns of patients treated
with Canephron® N in the first trimester of pregnancy. Blue: Statistical data of newborns from the same clinics whose mothers did not take
Canephron® N
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critical period of pregnancy, we conducted a retro-
spective analysis of a systematically selected study
population. As a comparator group, the national stat-
istical data of the general Kiev population during the
same period was used. The main findings from our
study indicated no increased incidence of congenital
birth defects in the study population, which consisted
of women who had used Canephron® N during the
first trimester of pregnancy. Further analysis of the
RR supported these findings, indicating the absence
of any effects of Canephron® N on the risk of con-
genital birth defects. Finally, the majority of newborns
whose mothers had received Canephron® N treatment
during the first trimester of pregnancy had an excel-
lent general status immediately after birth, as assessed
using the Apgar scoring system.
The safety findings from our study support the
previously-published findings on Canephron® N in the
prevention and treatment of UTIs and related diseases
in pregnant women. Three studies have investigated the
effects of Canephron® N in pregnant women, focusing pri-
marily on efficacy [35–37]. The study by Ordzhonikidze
et al. included 300 pregnant women with a range of urin-
ary pathologies including asymptomatic bacteriuria, gesta-
tional, exacerbation of chronic pyelonephritis, or chronic
urinary disease without exacerbations [36]. An independ-
ent study by Medved et al. included 30 pregnant women
with type I diabetes mellitus who had gestational pyelo-
nephritis or exacerbations of chronic pyelonephritis
[35]. The third study was a prospective, randomized
study that included 85 pregnant women with a range of
renal pathologies [38]. In all three studies, Canephron®
N was administered alongside standard therapy and
had beneficial effects in pregnant women suffering from
various renal pathologies. Although no detailed safety
analyses were performed in these studies, Canephron®
N showed a good safety and tolerability profile across
all the study populations [27]. It should be noted that
the drug was not administered in the first trimester of
pregnancy in all three studies.
Two additional studies investigated the potential ef-
fects of Canephron® N on the rates of congenital malfor-
mations [38, 39]. Repina et al. followed up 115 children
(aged 5 months–3.5 years) born to women who were
treated with Canephron® N during the second or third
trimester of pregnancy. The study reported no adverse
effects on the fetus during pregnancy and no post-
partum effects on the children born to mothers who had
been treated with the drug while pregnant [39]. A large
prospective-retrospective study evaluating the terato-
genic, embryotoxic and fetotoxic effects of Canephron®
N in 1647 women indicated no evidence of any develop-
mental or congenital effects [38]. Our data builds on the
findings from these studies, suggesting that the use of
Canephron® N during the first trimester of pregnancy is
not associated with teratogenic effects in the fetus.
The limitations of our study are related to its retro-
spective design, and the resulting lack of data on poten-
tial confounding factors that may have affected the
incidence of congenital birth defects in our study popu-
lation. Furthermore, the number of individuals included
in the study population was relatively small (a total of
384) and in (48.95 %) cases, Canephron N was used as
part of combination therapy (alongside with the antibac-
terial agents phosphomycin, aminopenicillins, and ceph-
alosporins). It is also worth mentioning that some of the
users might have experienced miscarriage due to the “all
or nothing” rule early in pregnancy and such cases are
not reported in the present study.
Conclusions
The results from our study indicate that the use of
Canephron® N during the first trimester of pregnancy
was not associated with any teratogenic effects on the
fetus, and had no effects on the general condition of the
newborn infants.
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